title: [Clinical evaluation of long-term administration of terodiline hydrochloride for the treatment of patients with pollakisuria and incontinence].
abstract: We evaluated the effectiveness and side effects of long-term administration of terodiline hydrochloride in patients with chief complaints of pollakisuria or incontinence or both due to unstable bladder or neurogenic bladder associated with uninhibited contraction. The dose was 24 mg once daily. The symptoms such as pollakisuria and incontinence improved in 31 out of 41 patients (76%). Mild side effects were observed in 12 out of 47 patients (26%), which were thirst, dizziness, dysuria, urticaria and gastrointestinal symptoms. An increasing tendency of both maximum desire to void and compliance (p less than 0.10), and significant difference in maximum static pressure (p less than 0.05) were observed on urodynamic examinations before and after administration of this medicine. The results obtained from this study suggest that terodiline hydrochloride may be greatly recommended for patients with such symptoms as pollakisuria and incontinence.
authors.affiliation: Department of Urology, Hyogo College of Medicine.
authors.forename: Y
authors.initials: Y
authors.lastname: Tsujimoto
authors.forename: H
authors.initials: H
authors.lastname: Fujisue
authors.forename: H
authors.initials: H
authors.lastname: Shima
authors.forename: F
authors.initials: F
authors.lastname: Ikoma
authors.forename: T
authors.initials: T
authors.lastname: Sakurai
authors.forename: Y
authors.initials: Y
authors.lastname: Sato
authors.forename: M
authors.initials: M
authors.lastname: Tokizane
authors.forename: K
authors.initials: K
authors.lastname: Akiyama
authors.forename: S
authors.initials: S
authors.lastname: Kato
authors.forename: K
authors.initials: K
authors.lastname: Nakachi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002082:Butylamines / Q000008:administration & dosage* / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000008:administration & dosage* / Q000627:therapeutic use; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010276:Parasympatholytics / Q000008:administration & dosage* / Q000627:therapeutic use; D014549:Urinary Incontinence / Q000188:drug therapy*
chemical_list: D002082:Butylamines; D002121:Calcium Channel Blockers; D010276:Parasympatholytics; C010637:terodiline